Status:
COMPLETED
Insulin Resistance and Central Nervous System (CNS) Function in Type 2 Diabetes
Lead Sponsor:
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Conditions:
Insulin Resistance
Type 2 Diabetes Mellitus
Eligibility:
All Genders
55+ years
Phase:
PHASE4
Brief Summary
The purpose of this study is to examine the effects of treating insulin resistance on memory and attention, brain glucose utilization, and proteins in spinal fluid.
Detailed Description
Insulin resistant conditions such as impaired glucose tolerance, type 2 diabetes mellitus, and hyperinsulinemia have been associated with an increased risk for memory decline and for Alzheimer's disea...
Eligibility Criteria
Inclusion
- Impaired glucose tolerance OR mild type 2 diabetes mellitus OR normal blood sugar regulation
- Stable weight and activity level
Exclusion
- Medications for diabetes
- Dementia
- Medications with known effects on memory
- Serious neurologic disease or head trauma
- Serious systemic illness (e.g., renal failure or uncontrolled hypertension)
- Serious psychiatric illness (e.g., schizophrenia or bipolar disorder)
- Allergy to pioglitazone or nateglinide
Key Trial Info
Start Date :
November 1 2002
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 1 2006
Estimated Enrollment :
140 Patients enrolled
Trial Details
Trial ID
NCT00212290
Start Date
November 1 2002
End Date
December 1 2006
Last Update
February 15 2010
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
VA Puget Sound Health Care System (Seattle Campus)
Seattle, Washington, United States, 98108
2
VA Puget Sound Health Care System (American Lake Campus)
Tacoma, Washington, United States, 98493